N-α-Boc-N-δ-trityl-L-glutamine

N-α-Boc-N-δ-trityl-L-glutamine is a protected L-glutamine derivative featuring an α-amino group masked as a tert-butoxycarbonyl (Boc) carbamate, a δ-amide side chain characteristic of glutamine, and a trityl (triphenylmethyl, Trt) protecting group on the terminal amide nitrogen. The molecule therefore presents two orthogonally protected nitrogen sites (Boc on the α-amino and Trt on the side-chain amide), while retaining the glutamine carbon skeleton that supports peptide bond formation at the α-position after deprotection. The bulky, hydrophobic trityl group suppresses undesired side reactions during peptide coupling and can be removed under standard acid-mediated conditions, whereas the Boc group provides controlled liberation of the α-amine for stepwise assembly. The resulting reactivity profile aligns with peptide synthesis workflows that require selective deprotection, stable handling of amide functionality, and reliable conversion into downstream amino-acid building blocks and protected intermediates.

1. Peptide Synthesis

N-α-Boc-N-δ-trityl-L-glutamine is used in peptide synthesis as a glutamine-derived peptide building block where orthogonal N-protection supports controlled coupling and sequential deprotection. The α-Boc carbamate protects the amino nucleophile during activation of the carboxyl functionality, while the δ-Trt group helps maintain the side-chain amide nitrogen in a protected state to prevent branching or cross-linking during chain assembly. The glutamine backbone geometry and stereochemistry of the L-configuration align with standard amide bond formation strategies, enabling incorporation into peptide sequences that require glutamine side-chain integrity. Following selective deprotection of the Boc and/or trityl group, the compound can be converted into glutamine-containing peptide analogs suitable for biochemical research intermediate preparation.

2. Protected Amino Acids

N-α-Boc-N-δ-trityl-L-glutamine serves as a protected amino acid intermediate for N-protected glutamine chemistry where orthogonality between Boc and trityl enables stepwise functional group management. The α-amino protection as Boc supports predictable deprotection to regenerate the free amino group for subsequent derivatization, while the δ-amide nitrogen protected as trityl can be retained during early-stage transformations to reduce side reactions. The presence of the glutamine side-chain amide provides a handle for later functionalization after deprotection, including conversion to activated derivatives or incorporation into protected peptide fragments. The compound's protected nitrogen architecture makes it compatible with fine chemical synthesis routes that require controlled exposure of amine functionality and stable storage of the amide during multi-step processing.

3. Chemical Biology Labels

N-α-Boc-N-δ-trityl-L-glutamine can be applied in chemical biology workflows that construct glutamine-bearing molecular probes and labeling reagents through controlled side-chain amide availability. The protected δ-amide nitrogen helps preserve the glutamine side chain during peptide coupling or scaffold assembly, while selective removal of the trityl group can later expose the side-chain amide for conjugation chemistry. The α-Boc functionality supports incorporation into peptides or peptide-like constructs, enabling generation of glutamine-containing conjugates used as substrates, affinity handles, or structural probes in biomolecular interaction studies. Downstream derivatization of the liberated glutamine side chain can be used to access labeled peptide fragments, enabling synthesis of research intermediates for biomolecule modification and molecular recognition assays.

4. Peptidomimetics And SAR

N-α-Boc-N-δ-trityl-L-glutamine is suitable for peptidomimetic construction and structure-activity relationship studies where glutamine's side-chain amide participates in hydrogen-bonding and conformational tuning. The orthogonal protection pattern supports the assembly of peptide analogs in which glutamine is incorporated without premature side-chain activation, allowing systematic variation of adjacent residues while maintaining side-chain integrity. Selective deprotection strategies enable conversion into analogs bearing free glutamine functionality for subsequent modifications such as amide-to-activated-derivative transformations or controlled substitution chemistry. The stereodefined L-glutamine backbone supports reproducible analog libraries used for SAR-focused molecular design and comparative structure-function evaluation in applied research settings.

5. Pharmaceutical Manufacturing

N-α-Boc-N-δ-trityl-L-glutamine can be employed in pharmaceutical manufacturing contexts as a process-compatible protected amino acid input for producing glutamine-containing peptides and peptide intermediates. The dual N-protection strategy reduces the likelihood of uncontrolled side reactions during coupling steps, supporting reproducible intermediate formation for downstream purification and conversion into final peptide materials. The Boc and trityl protecting groups provide controlled deprotection windows that can be aligned with manufacturing flows requiring selective liberation of the α-amine and side-chain amide. The compound's defined stereochemistry and protected functional group set make it appropriate for industrial fine chemical synthesis where peptide building block preparation and controlled deprotection sequence design are central to batch consistency.

1. Effect of Short-Term Desiccation, Recovery Time, and CAPA-PVK Neuropeptide on the Immune System of the Burying Beetle Nicrophorus vespilloides

2. Zeta-potential-changing nanoparticles conjugated with cell-penetrating peptides for enhanced transfection efficiency

3. cRGD-functionalized, DOX-conjugated, and 64Cu-labeled superparamagnetic iron oxide nanoparticles for targeted anticancer drug delivery and PET/MR imaging

4. Tachykinin-related peptides modulate immune-gene expression in the mealworm beetle Tenebrio molitor L

5. Low bone turnover and low BMD in Down syndrome: effect of intermittent PTH treatment